FreePint for Biopharma
Jinfo Blog
7th October 2015
Abstract
Many global pharmaceutical companies with multiple divisions and widespread user populations, struggle to educate their users about the correct use of content that seems to be freely available on the open web. Libby Trudell explains how the FreePint Series "All About Usage," which ran from July to September, offers many insights about best practices for copyright and authentication which will be appreciated by information professionals in the pharma field.
Item
At a recent gathering of information professionals, a key concern raised by participants from biopharma companies was the risk of inappropriate content use as more and more open source content becomes discoverable.
Scientists often just assume that such content is available for free, when in fact it may be authorised only for academic use, or single use with no redistribution.
What's at Risk?
Large corporations with deep pockets are particularly are particularly at risk if the copyright holder decides to take legal action for use of content without permission.
Yet, scientists who are used to sharing research with colleagues are often not tuned into this issue. "Everything we've talked about comes down to rights management," was the final comment of one biopharma information centre manager.
Managing the Rights Process
Our customers in biopharma companies benefit from FreePint's coverage of this topic as well as other the timely issues.
FreePint interviewed the James Bennett of the UK's Copyright Licensing Agency to find out more about their licensing arrangements for the pharma, life sciences and STM sectors, and how they cater for the unique collaborative nature of the pharma development cycle.
Clare Painter discusses "How Much Will it Cost to Use Someone Else's Copyright Content", Irene Koren highlights the need for "Respecting the Ownership of Knowledge" and Isabelle Garcia outlines "Approaches to Authentication". These are some of the many FreePint subscription articles and reports of particular interest to pharmaceutical information centre managers published in the last few months.
If you have a FreePint Subscription, you have access to all our Content. Click any link below to login to view, save or share any item, register for webinars, and download reports. If not, or if you're not sure, click here to find out more about a FreePint Subscription.
Recent Subscription Content of particular interest to our customers in pharmaceutical companies:
Articles
- At the Commercial Frontier with Text and Data Mining
- Respecting the Ownership of Knowledge
- Source Update for EBSCO
- RightFind XML for Mining - a Q&A with Copyright Clearance Center (CCC)
- An Introduction to Digital Rights Management
- Content Management Tools That Really Can Deliver
- All About Usage - the Content Journey
- Approaches to Authentication
Reports
- FreePint Report: Product Review of FirstWord Pharma PLUS
- FreePint Report: Product Review of PatentAdvisor
- FreePint Report: Product Review of EndNote
- FreePint Report: Research into Skills Development 2015
- FreePint Report: Research into Authentication
Webinars - recordings available to view for anyone with a FreePint Subscription
- Corporate Market for Ebooks: a Look at the Research
- Do You Know Your Skills Objectives?
- Recommit to Risk Management - A Strategic Value Information Practitioners Can Provide
Webinars - upcoming
- What We Learned about Usage - 16th - 18th November 2015
Community session
11th December 2024
2025 strategic planning; evaluating research reports; The Financial Times, news and AI
5th November 2024
How are information managers getting involved with AI? Navigating privacy, ethics, and intellectual property
- 2025 strategic planning; evaluating research reports; The Financial Times, news and AI
5th November 2024 - All recent Jinfo Subscription content
31st October 2024 - End-user training best practice research
24th October 2024
- Jinfo Community session (TBC) (Community) 23rd January 2025
- Clinic on contracting for AI (Community) 11th December 2024
- Discussing news and AI strategies with the Financial Times (Community) 21st November 2024